Medgenics (MDGN +13.2%) gets a pop today after being granted a patent by the USPTO protecting the use of the company's Epodure Biopump technology for the treatment of anemia. The patent agency also allowed claims covering a similar method for delivery underlying it's Hemodure Biopump technology for sustained prophylactic treatment of hemophilia. MDGN's global portfolio now includes 36 patents issued, with 81 more pending.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs